Russia establishes its National Quality Infrastructure Council

Print 20 March 2018
GMP News

On March 14, Denis Manturov, the Russian Minister of Industry and Trade, chaired a meeting of the State Commission on Counteraction to Illegal Circulation of Industrial Products.

The Minister said that, ensuring the “market purity” would require, in addition to providing more preferences for entrepreneurs operating strictly within the legal field, to guarantee to potential consumers that they purchase genuine rather than counterfeit and falsified products.

“This is the primary aim of labeling mechanism which, according to instructions from the Prime Minister, should cover a wide range of products by 2024. Last year, we launched a drug labeling experiment. By implementing this tool, we already managed to prevent a number of crimes involving the falsification and distribution of substandard drugs,” said the Minister of Industry and Trade.

According to Denis Manturov, in order to combat the illegal circulation, it is equally important to develop the quality assurance infrastructure, including the standardization, metrology, accreditation, and conformity assessment. In addition, the results of rolling sample studies conducted by Roskachestvo (Russian Quality System) should be used to initiate a timely response to identified facts of illegal circulation. In this regard, it was decided that a representative of the Prosecutor General’s Office would work in the State Commission on a permanent basis.

In addition, the meeting of the State Commission decided to establish the National Quality Infrastructure Council.

Source

Return

All Portfolio

MEDIA CENTER

  • NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the start of construction of a plant for the production of sterile injectable drugs as part of its long-term strategy to localize innovative medicines and technologies of their development and production in Russia. The plant will be built in the industrial park “Vorsino” in the Kaluga region.